CEDAR KNOLLS, N.J.,
Feb. 27, 2019 /PRNewswire/
-- MYOS RENS Technology Inc. ("MYOS" or "the Company")
(NASDAQ: MYOS), an advanced nutrition company and the owner of
Fortetropin®, a proprietary bioactive composition
derived from fertilized egg yolk that helps build lean muscle,
announced that it has signed an agreement with Kansas State University College of Veterinary Medicine to
evaluate the impact of Fortetropin on quality of life and activity
in geriatric dogs. The study will be performed under the
supervision of Kenneth R. Harkin,
DVM, DACVIM (SAIM), Professor and Section Head, Small Animal
Internal Medicine.
This veterinary clinical study follows the announcement of
positive results from a randomized, double-blind,
placebo-controlled study that examined the impact of Fortetropin on
recovery following tibial plateau leveling osteotomy (TPLO) surgery
in dogs. Dr. Harkin also served as the Principal Investigator
for the earlier study and presented the results at the North
American Veterinary Community (NAVC) Conference / VMX on
January 20, 2019.
Forty (40) geriatric dogs that suffer from three of the
following conditions will be recruited to participate in the study:
weakness, weight loss, slowed or altered mobility, or exercise
intolerance. Twenty (20) of these dogs will be assigned to
receive Fortetropin and 20 will be assigned to receive a
macronutrient-matched placebo. All of the dogs participating
in the study will be fitted with an activity collar. After
two weeks of initial activity monitoring, the dogs will receive
either Fortetropin or placebo for 12 weeks. The Quality of
Life (QOL) assessment will be based on the Liverpool Osteoarthritis
in Dogs (LOAD) Questionnaire.
Dr. Harkin commented, "Pet owners often remark that their dog is
"slowing down" as they enter their golden years. Although
osteoarthritis is often tipped as the culprit, the loss of muscle
mass associated with old age is an under-appreciated cause.
Geriatric dogs with muscle mass loss fatigue easily, which by
itself can negatively impact their quality of life. Numerous
testimonials by pet owners suggest that Fortetropin supplementation
has a positive influence on quality of life and activity levels in
geriatric dogs. Based on these reports and the positive
results from our previous study showing improvement in recovery
from orthopedic surgery, I believe that a study examining the
impact of Fortetropin on geriatric dogs is warranted."
Joseph Mannello, CEO, MYOS,
commented, "I believe that MYOS is uniquely positioned to address
muscle health in animals. We have a very strong intellectual
property position that forms the backbone of our animal health
business. What distinguishes MYOS from its competitors is the
unique formulation of our products which are supported by rigorous
scientific research conducted at leading academic
institutions. We are very pleased to work with Kansas State University on another veterinary
clinical research study, supporting our potential 'game-changing'
efforts in animal health."
About MYOS RENS Technology Inc.
MYOS RENS
Technology Inc. (MYOS), "The Muscle Company®", is a
Cedar Knolls, NJ-based advanced
nutrition company that develops and markets products that improve
muscle health and performance. MYOS is the owner of
Fortetropin®, a fertilized egg yolk-based product
manufactured via a proprietary process to retain and optimize its
biological activity. Fortetropin has been clinically shown to
increase muscle size and lean body mass in conjunction with
resistance training. MYOS believes Fortetropin has the potential to
redefine existing standards of physical health and wellness. For
more information, please visit www.MYOSRENS.com.
Forward-Looking Statements
Any statements in
this release that are not historical facts are forward-looking
statements. Actual results may differ materially from those
projected or implied in any forward-looking statements. Such
statements involve risks and uncertainties, including but not
limited to those relating to product and customer demand, market
acceptance of our products, the ability to create new products
through research and development, the successful results of
strategic initiatives, the successful launch of our products,
including Qurr®,
Yolked®, MYOS Enteral
Nutrition Formula™ and MYOS Canine Muscle
Formula® products, the
success of our research and development, the results of the
clinical evaluation
of Fortetropin® and
its effects including the clinical study described herein, the
ability to enter into new partnership opportunities and the success
of our existing partnerships, the ability to generate the
forecasted revenue stream and cash flow from sales of our products,
the ability to increase our revenue and gross profit margins, the
ability to achieve a sustainable, profitable business, the effect
of economic conditions, the ability to protect our intellectual
property rights, competition from other providers and products, the
continued listing of our securities on the Nasdaq Stock Market,
risks in product development, our ability to raise capital to fund
continuing operations, and other factors discussed from time to
time in our filings with the Securities and Exchange
Commission. We undertake no obligation to update or revise any
forward-looking statement for events or circumstances after the
date on which such statement is made except as required by
law.
These statements have not been evaluated by the Food and Drug
Administration. Our products are not intended to diagnose, treat,
cure or prevent any disease.
Investor Relations:
Porter LeVay & Rose
Michael Porter, President
Phone: 212-564-4700
Email: MYOS@plrinvest.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/myos-rens-technology-announces-initiation-of-a-study-at-kansas-state-university-to-evaluate-the-impact-of-fortetropin-on-quality-of-life-and-activity-in-geriatric-dogs-300802718.html
SOURCE MYOS RENS Technology